Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11

Benzinga Newsdesk www.benzinga.com Neutral 87.5%

Neg 0% Neu 87.5% Pos 0%

Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide
OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan

Comments

No comments yet. Be the first!